You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Covance hopes to improve and accelerate oncology clinical trial matching with the Tempus technology platform and network.
Healthcare providers need multiplexed tests that can differentiate the flu from the coronavirus so they can treat patients quickly and appropriately.
Mission Bio will use a recent $70 million funding round to develop quality control assays using its Tapestri single-cell analysis platform.
The FDA reissued the EUA after analyzing LabCorp data that showed the test could detect SARS-CoV-2 in a general asymptomatic population.
Replacing nasopharyngeal swabs with saliva samples or nasal swabs could increase throughput and convenience, as well as relieve reagent and equipment shortages.
LabCorp has received US Food and Drug Administration authorization for at-home sample collection for its COVID-19 test, 360Dx reports.
Among other projects, PacBio is working with LabCorp to sequence a large number of SARS-CoV-2 genomes from de-identified positive samples.
MicroGen Dx's Texas-based lab is the only commercial laboratory in the US offering sputum testing for SARS-CoV-2.
Illumina, LabCorp, and Providence healthcare will join the effort to collect COVID-19 patient samples in the US for immune cell receptor sequencing.
Hologic and LabCorp became the third and fourth commercial test makers to receive EUA designation for assays to detect the coronavirus that causes COVID-19.
Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.
Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.
The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.
This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.